- $26.50m
- $18.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.45 | ||
| Price to Tang. Book | 3.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -223.53% | ||
| Return on Equity | -1038.73% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 7.97 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Directors
- Jacob Harel NEC (65)
- Amir Weisberg CEO (65)
- Dikla Akselbrad CFO (47)
- Shaul Mukhtar COO (65)
- Noam Emanuel CSO (62)
- Dalit Hazan VPR (50)
- Stanley Stern DRC (63)
- Yechezkel Barenholz IND (79)
- Nir Dror IND (44)
- Chaim Hurvitz IND (61)
- Itzhak Krinsky IND (68)
- Anat Segal IND (54)
- Robert Stein IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 24th, 2008
- Public Since
- June 26th, 2020
- No. of Shareholders
- 48
- No. of Employees
- 57
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 10,190,904
- Address
- 18 Hasivim Street,, PETAH TIKVA, 4917002
- Web
- https://www.polypid.com
- Phone
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for PYPD
Q1 2025 PolyPid Ltd Earnings Release
Q2 2025 PolyPid Ltd Earnings Release
Similar to PYPD
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Polypid share price?
As of Today at 22:41 UTC, shares in Polypid are trading at $2.60. This share price information is delayed by 15 minutes.
How has the Polypid share price performed this year?
Shares in Polypid last closed at $2.60 and the price had moved by -45.91% over the past 365 days. In terms of relative price strength the Polypid share price has underperformed the S&P500 Index by -50.07% over the past year.
What are the analyst and broker recommendations for Polypid?
The overall consensus recommendation for Polypid is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Polypid dividend yield?
Polypid does not currently pay a dividend.
Does Polypid pay a dividend?
Polypid does not currently pay a dividend.
When does Polypid next pay dividends?
Polypid does not currently pay a dividend.
How do I buy Polypid shares?
To buy shares in Polypid you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Polypid?
As of the previous close price of $2.60, shares in Polypid had a market capitalisation of $26.50m.
Where are Polypid shares listed?
Here are the trading details for Polypid:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PYPD
What kind of share is Polypid?
Based on an overall assessment of its quality, value and momentum Polypid is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Polypid share price forecast for 2025?
The analyst consensus target price for shares in Polypid is $11.33. That is 335.77% above the last closing price of $2.60.
Analysts covering Polypid currently have a consensus Earnings Per Share (EPS) forecast of -$1.85 for the next financial year.
Find out moreWhat is the trend in the Polypid share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Polypid. Over the past six months, its share price has underperformed the S&P500 Index by -17.46%.
As of the last closing price of $2.60, shares in Polypid were trading -19.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Polypid PE Ratio?
The Polypid PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Polypid?
Polypid's management team is headed by:
- Jacob Harel - NEC
- Amir Weisberg - CEO
- Dikla Akselbrad - CFO
- Shaul Mukhtar - COO
- Noam Emanuel - CSO
- Dalit Hazan - VPR
- Stanley Stern - DRC
- Yechezkel Barenholz - IND
- Nir Dror - IND
- Chaim Hurvitz - IND
- Itzhak Krinsky - IND
- Anat Segal - IND
- Robert Stein - IND